Ovarian Cancer | Tumor

CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.

HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer

January 13th 2025, 4:00pm

Article

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

My Top 10 Hacks for Surviving with Cancer in the Infusion Room

January 8th 2025, 6:00pm

Article

Every treatment bag should include an unlimited supply of humor. Stuff will happen. It’ll be hard, but you may learn to laugh about it later, like I did.

FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer

January 2nd 2025, 10:00pm

Article

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

Reflecting on 2024 Following an Ovarian Cancer Diagnosis

December 26th 2024, 6:00pm

Article

Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.

Nemvaleukin Shows Manageable Safety Profile in Advanced Solid Tumors

December 3rd 2024, 8:00pm

Article

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

Counting Blessings Is Key to Living With Cancer

November 28th 2024, 6:00pm

Article

In the cancer world — or anywhere — the ability to give thanks in the midst of trials is an acquired skill. It must be practiced.

My Top 10 List for Living With Cancer

November 19th 2024, 6:00pm

Article

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Application Submitted to FDA for Avutometinib Plus Defactinib in Rare Ovarian Cancer

November 1st 2024, 9:00pm

Article

The FDA received the New Drug Application for avutometinib plus defactinib as a potential treatment option for previously treated low-grade serous ovarian cancer.

Current Treatment May Be Superior to Recentin In Ovarian Cancer

October 30th 2024, 3:00pm

Article

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.

Avutometinib and Defactinib May Benefit Some with Ovarian Cancer

October 21st 2024, 9:00pm

Article

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.